برنامج تطوير مهنة الصيدلة - PPDPROGRAM

➡️Lumify (brimonidine tartrate) Ophthalmic Solution Date of Approval: December 22, 2017 Company: Bausch + Lomb Treatment for: Ocular Redness Lumify (brimonidine tartrate) is an over-the-counter (OTC) formulation of the alpha-adrenergic agonist brimonidine indicated for use in the treatment of ocular redness. https://t.me/ppdprogram

➡️Steglujan (ertugliflozin and sitagliptin) Tablets Date of Approval: December 19, 2017 Company: Merck & Co., Inc. Treatment for: Diabetes, Type 2 Steglujan (ertugliflozin and sitagliptin) is a sodium glucose co-transporter 2 (SGLT2) inhibitor, and dipeptidyl peptidase-4 (DPP-4) inhibitor combination used to improve glycemic control in adults with type 2 diabetes. https://t.me/ppdprogram

➡️Giapreza (angiotensin II) Injection - formerly LJPC-501 Date of Approval: December 21, 2017 Company: La Jolla Pharmaceutical Company Treatment for: Hypotension, Shock Giapreza (angiotensin II) is a synthetic human angiotensin II vasoconstrictor indicated for the treatment of hypotension in adults with septic or other distributive shock. https://t.me/ppdprogram

➡️Rhopressa (netarsudil) Ophthalmic Solution Date of Approval: December 18, 2017 Company: Aerie Pharmaceuticals, Inc. Treatment for: Glaucoma Rhopressa (netarsudil ophthalmic solution) is a Rho kinase inhibitor for the treatment of open-angle glaucoma or ocular hypertension. https://t.me/ppdprogram

➡️Sinuva (mometasone furoate) Sinus Implant Date of Approval: December 8, 2017 Company: Intersect ENT, Inc. Treatment for: Nasal Polyps Sinuva (mometasone furoate) is a corticosteroid-eluting sinus implant indicated for the treatment of recurrent nasal polyp disease. https://t.me/ppdprogram

➡️Ozempic (semaglutide) Injection Date of Approval: December 5, 2017 Company: Novo Nordisk Treatment for: Diabetes, Type 2, Cardiovascular Risk Reduction Ozempic (semaglutide) is a glucagon-like peptide-1 (GLP-1) analog for the treatment type 2 diabetes, and to reduce the risk of major cardiovascular events in patients with type 2 diabetes and known heart disease. https://t.me/ppdprogram

➡️Ascor (ascorbic acid) Injection Date of Approval: October 2, 2017 Company: McGuff Pharmaceuticals, Inc. Treatment for: Scurvy Ascor (ascorbic acid) is an intravenous vitamin C formulation indicated for the short term treatment of scurvy. https://t.me/ppdprogram

➡️Bydureon BCise (exenatide) Extended-Release Injectable Suspension Date of Approval: October 20, 2017 Company: AstraZeneca Treatment for: Diabetes, Type 2 Bydureon BCise (exenatide) is a glucagon-like peptide-1 (GLP-1) receptor agonist indicated to improve glycemic control in patients with type 2 diabetes. https://t.me/ppdprogram

➡️Fiasp (insulin aspart) Injection Date of Approval: September 29, 2017 Company: Novo Nordisk Treatment for: Diabetes, Type 1, Diabetes, Type 2 Fiasp (insulin aspart) is a rapid-acting human insulin analog indicated to improve glycemic control in adults and children with diabetes mellitus. Fiasp is a newer formulation of NovoLog, in which the addition of niacinamide (vitamin B3) helps to increase the speed of initial insulin absorption. https://t.me/ppdprogram

➡️Xhance (fluticasone propionate) Nasal Spray - formerly OPN-375 Date of Approval: September 18, 2017 Company: OptiNose US Inc. Treatment for: Nasal Polyps Xhance (fluticasone propionate) is a topical nasal corticosteroid indicated for the treatment of nasal polyps. https://t.me/ppdprogram

➡️Trelegy Ellipta (fluticasone furoate, umeclidinium and vilanterol) Inhalation Powder Date of Approval: September 18, 2017 Company: GlaxoSmithKline Treatment for: COPD, Asthma, Maintenance Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanterol) is an inhaled corticosteroid, long-acting muscarinic antagonist (LAMA), and long-acting beta2-adrenergic agonist (LABA) combination indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD), and the maintenance treatment of asthma in patients aged 18 years and older. https://t.me/ppdprogram

➡️Solosec (secnidazole) Oral Granules Date of Approval: September 15, 2017 Company: Lupin Pharmaceuticals, Inc. Treatment for: Bacterial Vaginosis, Trichomoniasis Solosec (secnidazole) is a nitroimidazole antimicrobial for use as a single-dose oral therapy in the treatment of bacterial vaginosis (BV) and trichomoniasis. https://t.me/ppdprogram

➡️KedRAB (rabies immunoglobulin human) Injection Date of Approval: August 23, 2017 Company: Kamada Ltd. and Kedrion S.p.A. Treatment for: Rabies Prophylaxis KedRAB [rabies immunoglobulin (human)] is a human plasma derived anti-rabies immunoglobulin indicated for post-exposure prophylaxis (PEP) of rabies infection. https://t.me/ppdprogram

➡️CaroSpir (spironolactone) Oral Suspension Date of Approval: August 4, 2017 Company: CMP Pharma, Inc. Treatment for: Heart Failure, Edema, High Blood Pressure CaroSpir (spironolactone) is an oral suspension formulation of the potassium-sparing diuretic spironolactone indicated for the treatment of heart failure, management of edema, and for use as an add-on therapy in the treatment of hypertension. https://t.me/ppdprogram

➡️Vabomere (meropenem and vaborbactam) Injection - formerly Carbavance Date of Approval: August 29, 2017 Company: The Medicines Company Treatment for: Urinary Tract Infection Vabomere (meropenem and vaborbactam) is a carbapenem and beta-lactamase inhibitor combination for the treatment of complicated urinary tract infections (cUTIs). https://t.me/ppdprogram

➡️(benznidazole) Tablets Date of Approval: August 29, 2017 Company: Chemo Research, S. L. Treatment for: Chagas Disease Benznidazole is an antiprotozoal indicated for the treatment of Chagas disease, or American trypanosomiasis, a parasitic infection caused by Trypanosoma cruzi. https://t.me/ppdprogram

➡️Endari (L-glutamine) Oral Powder Date of Approval: July 7, 2017 Company: Emmaus Life Sciences Inc. Treatment for: Anemia, Sickle Cell Endari (L-glutamine) is orally-administered pharmaceutical grade L-glutamine (PGLG), an amino acid formulation to relieve pain, swelling and other complications of sickle cell anemia. https://t.me/ppdprogram

➡️Baxdela (delafloxacin) Tablets and Injection Date of Approval: June 19, 2017 Company: Melinta Therapeutics Treatment for: Skin and Structure Infection, Pneumonia Baxdela (delafloxacin) is a fluoroquinolone antibacterial indicated for the treatment of acute bacterial skin and skin structure infections (ABSSSI) and community-acquired bacterial pneumonia (CABP) caused by designated susceptible bacteria. https://t.me/ppdprogram

➡️Symjepi (epinephrine) Injection Date of Approval: June 15, 2017 Company: Adamis Pharmaceuticals Corporation Treatment for: Allergic Reactions Symjepi (epinephrine) is a non-selective alpha and betaadrenergic receptor agonist in a single-dose, pre-filled syringe for use the emergency treatment of allergic reactions (Type I) including anaphylaxis. https://t.me/ppdprogram

➡️Rebinyn (coagulation factor IX (recombinant), glycopegylated) Injection Date of Approval: May 31, 2017 Company: Novo Nordisk Treatment for: Hemophilia B Rebinyn (coagulation factor IX (recombinant), glycopegylated is an extended-half-life recombinant DNA-derived coagulation factor IX concentrate for the treatment and control of bleeding episodes in patients with hemophilia B. https://t.me/ppdprogram